Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ: EXEL )

37.27 +1.62 (+4.54%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,201,249
Open 36.23
Bid (Size) 37.10 (2)
Ask (Size) 37.75 (7)
Prev. Close 35.65
Today's Range 36.05 - 37.31
52wk Range 20.02 - 37.31
Shares Outstanding 315,048,788
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BeiGene Stock Meets 80-Plus RS Rating Benchmark
One key metric to look for in a stock is an 80-plus Relative Strength Rating. BeiGene stock just hit that mark, with a jump to 84 Wednesday. 
Via Investor's Business Daily
15 Analysts Have This To Say About Exelixis
Via Benzinga

Performance

YTD
+9.81%
+9.81%
1 Month
+3.33%
+3.33%
3 Month
+26.98%
+26.98%
6 Month
+65.57%
+65.57%
1 Year
+65.35%
+65.35%

More News

Read More
BridgeBio Pharma Stock Earns 87 RS Rating
Via Investor's Business Daily
NASDAQ:EXEL appears to be flying under the radar despite its strong fundamentals.
Via Chartmill
SpringWorks Therapeutics Stock Sees RS Rating Jump To 86
Via Investor's Business Daily
Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025
From Exelixis, Inc.
Via Business Wire
In the world of growth stocks, NASDAQ:EXEL shines as a value proposition.
Via Chartmill
(EXEL) - Analyzing Exelixis's Short Interest
Via Benzinga
Do Not Get Caught Holding Story Stocks- The Market Is Unforgiving
Via Talk Markets
Topics Stocks / Equities
Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Peering Into Exelixis's Recent Short Interest
Via Benzinga
Expert Outlook: Exelixis Through The Eyes Of 19 Analysts
Via Benzinga
NASDAQ:EXEL is showing decent growth, but is still valued reasonably.
Via Chartmill
SpringWorks Therapeutics Stock Gets A RS Rating Lift
Via Investor's Business Daily
Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
From Exelixis, Inc.
Via Business Wire
Arcellx Stock Earns 82 Relative Strength Rating
Via Investor's Business Daily
Investors should take notice of NASDAQ:EXEL—it offers a great deal for the fundamentals it presents.
Via Chartmill
This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Via Benzinga
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
Via Benzinga
2 Biotech Stocks to Buy Hand Over Fist in December
Via The Motley Fool
End Of Year Rally: 3 Stocks To Watch (InterDigital, Futu Holdings, Exelixis)
Via Talk Markets
Topics Stocks / Equities
Ten Young Ones
Via Talk Markets
Topics Stocks / Equities
NASDAQ:EXEL appears to be flying under the radar despite its strong fundamentals.
Via Chartmill
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December
From Exelixis, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.